随着GLP-1减肥药物的广泛推广，健康专家们对其营销策略提出了担忧。体重污名化研究专家维吉·托瓦尔认为，这一时代"极具反身体积极性"[1]。专家指出，虽然GLP-1药物具有正当的医学用途，但其营销活动频繁利用体重污名化和不健康的身体形象来销售产品，这对易感人群的心理健康造成了负面影响[1]。
心理学教授杰玛·夏普指出，体重污名化存在强有力的科学证据表明会导致"负面健康后果"[1]。营养科学家艾玛·贝克特曾使用Ozempic药物来缓解慢性疼痛，但后来因药物副作用而停止使用[1]。
在GLP-1时代保持积极身体形象需要采取多项策略。托瓦尔提议使用"这是广告，不是真相"这样的简单短语来识别饮食文化营销[1]。专家强调体重本身不是衡量健康的准确标准，人们应该将关注焦点从外形转向身体功能，同时需要管理社交媒体内容并设置心理边界[1]。
As GLP-1 weight-loss medications gain popularity, experts warn that their marketing strategies are reinforcing harmful body image standards and weight stigma. Weight stigma researcher Virgie Tovar describes the current era as "deeply anti-body positive," highlighting how pharmaceutical companies exploit insecurities about body image to sell these drugs [1]. While GLP-1 medications have legitimate medical applications, the promotional messaging surrounding them disproportionately affects vulnerable populations and undermines mental health [1].
The psychological toll of weight stigma is well-documented. Psychology professor Gemma Sharp points to robust evidence demonstrating that weight-based discrimination causes "negative health outcomes" [1]. Nutritional scientist Emma Beckett firsthand experienced the complications of GLP-1 use, having taken Ozempic to manage chronic pain before discontinuing the medication due to adverse side effects [1]. Experts emphasize that weight alone is not a reliable indicator of health and that individuals should prioritize body function over appearance [1].
To maintain a positive body image amid pervasive diet culture messaging, Tovar recommends practical strategies such as using the simple phrase "this is an advertisement, not the truth" to identify marketing disguised as health guidance [1]. Additionally, managing social media consumption, focusing on what the body can do rather than how it looks, and establishing firm mental boundaries can help people navigate the GLP-1 era with greater resilience [1].